ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

FDBK Feedback Plc

102.50
-2.50 (-2.38%)
Last Updated: 10:19:31
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Feedback Plc LSE:FDBK London Ordinary Share GB00BJN59X09 ORD 50P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -2.50 -2.38% 102.50 100.00 105.00 105.00 102.50 105.00 13,665 10:19:31
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Electronic Computers 1.03M -2.92M -0.2188 -4.68 13.67M

Feedback PLC Director/PDMR Shareholding (3698U)

02/12/2021 10:20am

UK Regulatory


Feedback (LSE:FDBK)
Historical Stock Chart


From Apr 2021 to Apr 2024

Click Here for more Feedback Charts.

TIDMFDBK

RNS Number : 3698U

Feedback PLC

02 December 2021

Feedback plc

Director Dealings

London , UK, 02 December 2021 - Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist clinical communication company, announces that further to the Fundraising, details of which were announced on 2 November 2021 and Admission which occurred on 30 November 2021, the following Directors' dealings as part of the Placing and Open Offer have completed:

Rory Shaw, Non Executive Chairman, has subscribed for 1,441,859 New Ordinary Shares through the Open Offer at the Issue Price of 0.7 pence per Ordinary Share.

Philipp Prince, Non Executive Director, has subscribed for 1,546,543 New Ordinary Shares through the Open Offer at the Issue Price of 0.7 pence per Ordinary Share.

Adam Denning, Non-Executive Director, has subscribed for 1,428,570 New Ordinary Shares through the Placing at the Issue Price of 0.7 pence per Ordinary Share.

Details of the Ordinary Shares held by these Directors are detailed in the table below:

 
 Director/       Position           Existing         Ordinary Shares     Total beneficial     Total interest 
  PDMR                               interest         purchased           interest in          in Company's 
                                     in Ordinary                          Ordinary Shares      issued share 
                                     Shares                                                    capital 
                 Non-Executive 
 Rory Shaw        Chairman          9,818,780        1,441,859           11,260,639           0.4% 
                ---------------  ---------------  ------------------  -------------------  ----------------- 
 Philipp         Non-Executive 
  Prince          Director          2,500,000        1,546,543           4,046,543            0.2% 
                ---------------  ---------------  ------------------  -------------------  ----------------- 
                 Non-Executive 
 Adam Denning     Director          1,530,411        1,428,570           2,958,981            0.1% 
                ---------------  ---------------  ------------------  -------------------  ----------------- 
 

The notification set out below, provides further details of such dealings:

 
 1     Details of the person discharging managerial responsibilities 
        / person closely associated 
 a)    Names                                    Rory Shaw 
                                                 Philipp Prince 
                                                 Adam Denning 
      ---------------------------------------  ------------------------------------------- 
 2     Reason for the notification 
      ------------------------------------------------------------------------------------ 
 a)    Position/status                          Non-Executive Chairman 
                                                 Non-Executive Director 
                                                 Non-Executive Director 
      ---------------------------------------  ------------------------------------------- 
 b)    Initial notification                     Initial notification 
        /Amendment 
      ---------------------------------------  ------------------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      ------------------------------------------------------------------------------------ 
 a)    Name                                     Feedback plc 
      ---------------------------------------  ------------------------------------------- 
 b)    LEI                                      213800UGOF2GT2U2RV90 
      ---------------------------------------  ------------------------------------------- 
 4     Details of the transaction(s): section to be repeated 
        for (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      ------------------------------------------------------------------------------------ 
 a)    Description of the                       Ordinary Shares of 0.25 pence each in 
        financial instrument,                    Feedback plc 
        type of instrument 
 
       Identification code                      GB0003340550 
 
 b)    Nature of the transaction                Purchase of Ordinary Shares 
      ---------------------------------------  ------------------------------------------- 
 c)    Price(s) and volume(s) 
                                                -------------------  ------------------- 
                                                 Price(s)             Volume(s) 
                                                -------------------  ------------------- 
                                                 0.7p                 1,441,859 
                                                -------------------  ------------------- 
                                                 0.7p                 1,546,543 
                                                -------------------  ------------------- 
                                                 0.7p                 1,428,570 
                                                -------------------  ------------------- 
 
 d)    Aggregated information 
 
  - Aggregated volume                      n/a 
 
  - Price 
 
 e)    Date of the transaction                  30 November 2021 
      ---------------------------------------  ------------------------------------------- 
 f)    Place of the transaction                 XLON 
      ---------------------------------------  ------------------------------------------- 
 

The capitalised terms used in this announcement have the same meanings as in the announcement published by the Company at 7.01 a.m. on 2 November 2021 unless otherwise stated.

Enquiries:

 
 Feedback plc                               +44 (0)1954 718072 
  Tom Oakley, CEO                            IR@fbk.com 
  Anesh Patel, CFO 
 
 Panmure Gordon (UK) Limited (NOMAD 
  and Broker) 
  Emma Earl/Freddy Crossley (Corporate 
  Finance) 
  Rupert Dearden (Corporate Broking)        +44 (0)20 7886 2500 
 
 Walbrook PR Ltd                            Tel: 020 7933 8780 or feedbackplc@walbrookpr.com 
 Paul McManus/Nick Rome/Nicholas Johnson    07980 541 893 or 07748 325 236 
                                             or 07884 664 686 
 

Notes to Editors

Feedback plc (AIM: FDBK) is a pioneer of regulated clinical communication products. Its core product, Bleepa, is a revolutionary medical imaging communications app, providing an easy-to-use, high quality tool to enable remote and secure communications between front-line clinicians and teams. Importantly, it is the only CE marked medical imaging communications platform on the NHSx clinical communications tools framework. Bleepa has unparalleled functionality for everyday practice and can be accessed from any internet-connected device, enabling control of patient cases when on the go.

Its highly scalable Software as a Service ("SaaS") based revenue model will provide increasing levels of visibility as the Company grows its customer base. With a growing distribution base and technology in place, the focus is on leveraging key relationships in order to drive sales both in the UK and internationally to all forms of care providers. As a fully certified medical device, Bleepa aims to disrupt the medical imaging communications market and, importantly, increase the accuracy and speed of clinical review.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHUPGRGPUPGGUP

(END) Dow Jones Newswires

December 02, 2021 05:20 ET (10:20 GMT)

1 Year Feedback Chart

1 Year Feedback Chart

1 Month Feedback Chart

1 Month Feedback Chart

Your Recent History

Delayed Upgrade Clock